TITLE

FDA APPROVES LILLY'S ZYPREXA FOR TWO ADOLESCENT INDICATIONS

PUB. DATE
December 2009
SOURCE
Psychiatry (1550-5952);Dec2009, Vol. 6 Issue 12, p10
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article reports on the U.S. Food and Drug Administration's (FDA) approval of the drug Zyprexa from Eli Lilly & Co. for the treatment of schizophrenia and bipolar I disorder in adolescents aged 13 to 17 years old. It notes that the tablet form of Zyprexa has been labeled to have side effects such as weight gain and hyperlipidemia. It adds that sedated adolescent patients are also likely to experience increases in prolactin levels and hepatic enzymes.
ACCESSION #
47477916

 

Related Articles

  • Antipsychotic cleared for bipolar disorder.  // Drug Topics;1/26/2004, Vol. 148 Issue 2, p8 

    Reports on the approval of olanzapine from Eli Lilly and Co. for the maintenance treatment of bipolar disorder by the U.S. Food and Drug Administration.

  • FDA approves Eli Lilly's Zyprexa in bipolar I disorder.  // PharmaWatch: CNS;September 2003, Vol. 2 Issue 9, p12 

    Reports on the approval of the U.S. Food and Drug Administration to Eli Lilly & Co.'s Zyprexa antidepressant as a combination therapy in bipolar I disorder. Basis for the regulatory decision; Safety and efficacy of Zyprexa; Response of patients taking Zyprexa.

  • FDA approves Lilly bipolar medication. Adams, Brent // Indianapolis Business Journal;1/5/2004, Vol. 24 Issue 44, p25A 

    Reports that the U.S. Food and Drug Administration has approved Symbyax, a drug developed by Eli Lilly and Co. to treat depressive episodes associated with bipolar disorders.

  • Lilly wins FDA approval for schizophrenia drug in adults.  // PharmaWatch: CNS;Feb2010, Vol. 9 Issue 2, p10 

    The article reports on the approval issued by the U.S. Food and Drug Administration (FDA) to the Eli Lilly and Co.'s extended release injectable suspension indicated for schizophrenia in adults, Zyprexa Relprevv. It notes that the FDA's approval was based on a clinical trial involving 2,054...

  • FDA APPROVES LILLY'S ZYPREXA RELPREVV FOR TREATMENT OF SCHIZOPHRENIA IN ADULTS.  // Psychiatry (1550-5952);Dec2009, Vol. 6 Issue 12, p9 

    The article reports on the U.S. Food and Drug Administration's (FDA) approval of the extended-release injectable suspension drug Zyprexa Relprevv from Eli Lilly & Co. for the treatment of schizophrenia in adult patients. It notes that Zyprexa Relprevv is a long acting formulation that can last...

  • ELI LILLY. Investor's Business Daily // Investors Business Daily;4/22/2014, pA02 

    The article reports on the U.S. Food and Drug Administration's (FDA) approval of the ramucirumab advanced stomach cancer drug from pharmaceutical firm Eli Lilly & Co.

  • Lilly gets a string of small victories.  // Indianapolis Business Journal;11/22/2010, Vol. 31 Issue 38, p13A 

    The article reports on the drug approval of Eli Lilly and Co.'s antidepressant Cymbalta to treat chronic pain by the Food and Drug Administration's (FDA) in the U.S.

  • Zyprexa era comes to an end for Lilly as generic versions begin.  // Indianapolis Business Journal;10/31/2011, Vol. 32 Issue 35, p13A 

    The article reports on the approval of Eli Lilly & Co.'s antipsychotic medication, Zyprexa, by the U.S. Food and Drug Administration (FDA) in 2011.

  • FDA signs off on manufacturing operations. Maurer, Katie // Indianapolis Business Journal;11/10/2003, Vol. 24 Issue 35, p37 

    Reports that the U.S. Food and Drug Administration has cleared Eli Lilly and Co. of manufacturing problems at two Indianapolis plants in Indiana. Approval of drugs; Availability of drugs.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics